Search Posts

Medical researchers have developed a new antifungal drug to help in the treatment oflife threatening invasive fungal infections such as invasive aspergillosis.
(University of Liverpool)


A new anti-fungal drug has been developed to treat fatal invasive fungal infection such as aspergillosis by researchers from University of Liverpool. This is the first anti-fungal agent discovered in the past three decades
(October 12, 2017; Comment of Heng)


University of Liverpool researchers, working with F2G Limited (Eccles, Manchester), have developed a new antifungal drug to help in the treatment of life threatening invasive fungal infections such as invasive aspergillosis.
Invasive fungal infections are common and often lethal. Despite optimal medical care mortality is 20-30% at six weeks and dramatically rises to 80-100% for drug resistant infection.
These infections occur most commonly in the context of leukemia and bone marrow transplantation and often in young patients with otherwise curable disease.
The researchers, led by Professor William Hope from the University's Antimicrobial Pharmacodynamics and Therapeutics (APT) Group, have characterised the biochemical and physiologic effects (pharmacodynamics) of F901318, which is the lead compound of the new class of drugs termed the 'orotomides'.
The 'orotomides', discovered by F2G Limited, have a novel mechanism of action which is the specific biochemical interaction through which a drug substance produces its pharmacological effect.
This is the first new class of antifungal agent to be discovered in the last three decades.
The study, which was supported by a research grant by F2G, has been published in mBio.
Clinical studies
APT's work provides the underpinning evidence for efficacy and dosage justification for the very first patients receiving the new drug. Such information is required by regulatory agencies such as the European Medicines Agency and the Food and Drug Administration before clinical studies can proceed.
Professor Hope, said: "Antifungal resistance represents a major global clinical challenge. This study provides the necessary information to enable F901318 to be developed for clinical use."

Story Source:
Materials provided by **University of Liverpool**. Note: Content may be edited for style and length.

Journal Reference:

  1. William W. Hope, Laura McEntee, Joanne Livermore, Sarah Whalley, Adam Johnson, Nicola Farrington, Ruwanthi Kolamunnage-Dona, Julie Schwartz, Anthony Kennedy, Derek Law, Michael Birch, John H. Rex. Pharmacodynamics of the Orotomides against Aspergillus fumigatus New Opportunities for Treatment of Multidrug-Resistant Fungal Disease. mBio, 2017; 8 (4): e01157-17 DOI: 10.1128/mBio.01157-17

University of Liverpool. "New antifungal drug." ScienceDaily. ScienceDaily, 6 October 2017. <>.

Tegn abonnement på

BioNyt Videnskabens Verden ( er Danmarks ældste populærvidenskabelige tidsskrift for naturvidenskab. Det er det eneste blad af sin art i Danmark, som er helliget international forskning inden for livsvidenskaberne.

Bladet bringer aktuelle, spændende forskningsnyheder inden for biologi, medicin og andre naturvidenskabelige områder som f.eks. klimaændringer, nanoteknologi, partikelfysik, astronomi, seksualitet, biologiske våben, ecstasy, evolutionsbiologi, kloning, fedme, søvnforskning, muligheden for liv på mars, influenzaepidemier, livets opståen osv.

Artiklerne roses for at gøre vanskeligt stof forståeligt, uden at den videnskabelige holdbarhed tabes.

Leave a Reply